DK0792160T3 - Glial-afledt neurofoisk faktor som et neurobeskyttende middel - Google Patents

Glial-afledt neurofoisk faktor som et neurobeskyttende middel

Info

Publication number
DK0792160T3
DK0792160T3 DK95935548T DK95935548T DK0792160T3 DK 0792160 T3 DK0792160 T3 DK 0792160T3 DK 95935548 T DK95935548 T DK 95935548T DK 95935548 T DK95935548 T DK 95935548T DK 0792160 T3 DK0792160 T3 DK 0792160T3
Authority
DK
Denmark
Prior art keywords
glial
derived
factor
neurophysical
gdnf
Prior art date
Application number
DK95935548T
Other languages
Danish (da)
English (en)
Inventor
David Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0792160T3 publication Critical patent/DK0792160T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK95935548T 1994-11-15 1995-11-13 Glial-afledt neurofoisk faktor som et neurobeskyttende middel DK0792160T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34082194A 1994-11-15 1994-11-15
PCT/IB1995/001004 WO1996014861A1 (fr) 1994-11-15 1995-11-13 Facteur neurotrophique derive des cellules gliales utilise en tant qu'agent neuroprotecteur

Publications (1)

Publication Number Publication Date
DK0792160T3 true DK0792160T3 (da) 2001-11-19

Family

ID=23335068

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95935548T DK0792160T3 (da) 1994-11-15 1995-11-13 Glial-afledt neurofoisk faktor som et neurobeskyttende middel

Country Status (13)

Country Link
US (1) US5733875A (fr)
EP (1) EP0792160B1 (fr)
JP (1) JPH10508839A (fr)
AT (1) ATE205088T1 (fr)
AU (1) AU691349B2 (fr)
CA (1) CA2204911C (fr)
DE (1) DE69522578T2 (fr)
DK (1) DK0792160T3 (fr)
ES (1) ES2159647T3 (fr)
IL (1) IL115966A (fr)
PT (1) PT792160E (fr)
WO (1) WO1996014861A1 (fr)
ZA (1) ZA959714B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
WO1997019693A1 (fr) * 1995-11-29 1997-06-05 Amgen Inc. Procede de traitement des neuropathies sensorielles utilisant un produit proteique du facteur neurotrophique derive d'une lignee de cellules gliales
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
BR9713055A (pt) 1996-11-15 2000-04-04 Genentech Inc Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
PT1223966E (pt) * 1999-10-29 2003-09-30 Biopharm Ges Biotechn Entwickl Utilizacao do gdnf para tratamento de defeitos na cornea
US20040197900A1 (en) * 2003-04-04 2004-10-07 Arnon Rosenthal Foggy
BRPI0710800A2 (pt) * 2006-04-25 2012-01-17 Univ California administração de fatores de crescimento para o tratamento de distúrbios de snc
JP2009535360A (ja) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2014152511A1 (fr) 2013-03-15 2014-09-25 The Jackson Laboratory Procédés favorisant la cicatrisation des plaies et la croissance des poils
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
AU2017357931A1 (en) 2016-11-10 2019-06-20 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
EP3973979A1 (fr) * 2020-09-25 2022-03-30 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth Protéine de jonction serrée (zonulae occludentes) à utiliser dans le traitement ou la prévention d'un trouble neurologique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU220795B1 (hu) * 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.

Also Published As

Publication number Publication date
AU691349B2 (en) 1998-05-14
EP0792160B1 (fr) 2001-09-05
CA2204911C (fr) 2002-07-23
IL115966A (en) 1999-11-30
WO1996014861A1 (fr) 1996-05-23
ATE205088T1 (de) 2001-09-15
DE69522578D1 (de) 2001-10-11
US5733875A (en) 1998-03-31
ES2159647T3 (es) 2001-10-16
PT792160E (pt) 2002-02-28
AU3752895A (en) 1996-06-06
JPH10508839A (ja) 1998-09-02
DE69522578T2 (de) 2002-07-11
IL115966A0 (en) 1996-01-31
CA2204911A1 (fr) 1996-05-23
EP0792160A1 (fr) 1997-09-03
ZA959714B (en) 1997-10-15

Similar Documents

Publication Publication Date Title
DK0792160T3 (da) Glial-afledt neurofoisk faktor som et neurobeskyttende middel
CA2098076A1 (fr) Prodrogues imidate de sulfamates anticonvulsivants pour usage pharmaceutique
HUP0203198A2 (hu) Tramadolvegyület és görcsoldó hatóanyagot tartalmazó gyógyászati készítmény, eljárás az előállítására és alkalmazása
HUP0100606A2 (hu) Keményített ricinusolajat tartalmazó tartós hatású injektálható készítmény
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
MX9207495A (es) Compuestos de tetrahidroisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
FI935847A (fi) L-DOPA-esterikoostumukset
DE69628163D1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
MY119375A (en) Treatment of tinnitus using neuroprotective agents
DE69631609D1 (en) Tricyclische erythromycinderivate
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
HUP0103781A2 (hu) Megismerési képesség javítására szolgáló gyógyszerkészítmények, melyek atipikus antipszihotikus szer és acetilkolinészteráz inhibitor kombinációját tartalmazzák
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
CA2459470A1 (fr) Composition pharmaceutique comprenant de la gabapentine ou un analogue de celle-ci et un .alpha.-aminoamide, et utilisation analgesique de ladite composition
ES2132101T3 (es) Procedimiento para la preparacion de un medicamento destinado a la administracion por via oral o topica en el tratamiento de leishmaniasis.
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
BR9809519A (pt) Sal, processo para fabricação e uso do mesmo, formulação farmacêutica, e, processo para prevenção ou tratamento de distúrbios cns e perturbações médicas relacionadas
WO1999045909A3 (fr) Inhibition de l'angiogenese
CA2192822A1 (fr) Utilisation d'agents immunosuppresseurs dans le traitement de la schizophrenie
MY133438A (en) Morpholinobenzamide salts